Covid 19 Research using Clinical Trials (Home Page)
Report for D013896: Thoracic Diseases NIH
(Synonyms: Thoracic Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
There is one clinical trial.
Clinical Trials
1 Dysphagia in Thoracic Surgical Patients: Incidence, Risk-factors, and Health Related Outcomes
The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing throacic surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.
NCT04487028 Thoracic Diseases Procedure: Fiberoptic Endoscopic Evaluation of Swallowing MeSH:Deglutition Disorders Thoracic Diseases
HPO:Dysphagia Oral-pharyngeal dysphagia
Primary Outcomes
Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
Measure: Penetration Aspiration Scale Time: Baseline
Secondary Outcomes
Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).
Measure: Yale Residue Severity Rating Scale Time: Baseline
Other Outcomes
Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.
Measure: Vocal Fold Mobility Impairment Time: Baseline
HPO Nodes
Primary Outcomes
Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
Measure: Penetration Aspiration Scale Time: BaselineSecondary Outcomes
Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).
Measure: Yale Residue Severity Rating Scale Time: BaselineOther Outcomes
Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.
Measure: Vocal Fold Mobility Impairment Time: Baseline